Marker Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 18, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 18, 2026

MRKR$0.99+10.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents


	FORWARD LOOKING STATEMENTS	ii
Part I · ·
Item 1.	Business	1
Item 1A.	Risk Factors	26
Item 1B.	Unresolved Staff Comments	62
Item 1C.	Cybersecurity	62
Item 2.	Properties	64
Item 3.	Legal Proceedings	64
Item 4.	Mine Safety Disclosure	64
Part II
Item 5.	Market For Registrant’s Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities	65
Item 6.	[Reserved]	65
Item 7.	Management’s Discussion And Analysis Of Financial Condition And Results Of Operations	65
Item 7A.	Quantitative And Qualitative Disclosures About Market Risk	77
Item 8.	Financial Statements	77
Item 9.	Changes In And Disagreements With Accountants On Accounting And Financial Disclosure	77
Item 9A.	Controls And Procedures	77
Item 9B.	Other Information	78
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	78
Part III
Item 10.	Directors, Executive Officers And Corporate Governance	79
Item 11.	Executive Compensation	79
Item 12.	Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters	79
Item 13.	Certain Relationships And Related Transactions, And Director Independence	79
Item 14.	Principal Accounting Fees And Services	79
Part IV
Item 15.	Exhibits, Financial Statement Schedules	80
	Signatures	84

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents